• Special Issue Topic

    The Era of Biologics in Allergy

    Submission Deadline: May 31, 2024

    Guest Editor

    Prof. Giovanni Paoletti E-Mail

    Assistant Professor in Internal Medicine - Humanitas University, Allergist “Personalized Medicine Asthma & Allergy Clinic” Istituto Clinico Humanitas - Humanitas Research Hospital, Milan, Italy

    Research Keywords: Asthma, allergen immunotherapy, real world evidence, nasal polyps, rhinitis

    About the Special Issue

    In recent decades the therapeutic approach towards severe allergic and immunological diseases has changed a lot. The previous vision of treating all patients with a single molecule has modified, giving more and more space to a precision medicine approach. To do this, the concept of phenotype and endotype has been developed in order to identify clinical characteristics and molecular mechanisms that do not work properly, in order to act in a tailor-made way on them. 

    The therapeutic response to these needs has been the “Biological drugs”, that have radically changed the approach towards many diseases ensuring a better quality of life for patients. 

    This Special Issue will deal with various aspects related to the application of biological drugs in a vast number of allergo-immunological pathologies in which they are currently used.

    Keywords: Biological drugs, precision medicine, new therapeutical approach

    Call for Papers

    Published Articles

    Open Access
    Mini Review
    Biologic drugs, a new therapeutic paradigm in moderate-severe atopic dermatitis
    Atopic dermatitis (AD), also referred to eczema, is a common inflammatory skin disease that usually presents during infancy or childhood but affects patients of all ages. It is a pruritic, chronic/r [...] Read more.
    Carlo Alberto Vignoli, Riccardo G. Borroni
    Published: December 08, 2023 Explor Asthma Allergy. 2023;1:198–206
    DOI: https://doi.org/10.37349/eaa.2023.00020
    Times Cited: 0
    Open Access
    Biologic drugs and allergen immunotherapy: potential allies
    Allergen-specific immunotherapy (AIT) is a proven efficacy treatment for allergic rhinitis (AR), asthma, and Hymenoptera venom allergy, but its use in food allergy (FA) is still under investigation. [...] Read more.
    Palma Carlucci ... Danilo Di Bona
    Published: October 20, 2023 Explor Asthma Allergy. 2023;1:126–141
    DOI: https://doi.org/10.37349/eaa.2023.00014
    Times Cited: 0
    Open Access
    Eosinophilic gastrointestinal disorders: new perspectives and the emerging role of biological therapies
    The advent of biological drugs has opened up new therapeutic possibilities in the field of eosinophilic gastro-intestinal diseases (EGIDs). EGIDs are chronic inflammatory diseases of the gastrointes [...] Read more.
    Francesca Losa, Arianna Cingolani
    Published: June 30, 2023 Explor Asthma Allergy. 2023;1:60–72
    DOI: https://doi.org/10.37349/eaa.2023.00009
    Times Cited: 0
    Open Access
    New therapeutic approaches with biological drugs for eosinophilic granulomatosis with polyangiitis
    Eosinophilic granulomatosis with polyangiitis (EGPA) is a multiorganic syndrome that affects the cardiovascular, neurologic, renal, and gastrointestinal systems with an incidence ranging from 0 case [...] Read more.
    Alejandra Carrón-Herrero ... Giovanni Paoletti
    Published: June 08, 2023 Explor Asthma Allergy. 2023;1:31–48
    DOI: https://doi.org/10.37349/eaa.2023.00006
    Times Cited: 0